0001493152-21-026394.txt : 20211026
0001493152-21-026394.hdr.sgml : 20211026
20211026215355
ACCESSION NUMBER: 0001493152-21-026394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211022
FILED AS OF DATE: 20211026
DATE AS OF CHANGE: 20211026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carillo Carlos N
CENTRAL INDEX KEY: 0001889694
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39871
FILM NUMBER: 211350494
MAIL ADDRESS:
STREET 1: 2100 E 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001833214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 853899721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 W. 41ST STREET
STREET 2: SUITE 202
CITY: MIAMI BEACH
STATE: FL
ZIP: 33140
BUSINESS PHONE: (305) 204-3338
MAIL ADDRESS:
STREET 1: 300 W. 41ST STREET
STREET 2: SUITE 202
CITY: MIAMI BEACH
STATE: FL
ZIP: 33140
FORMER COMPANY:
FORMER CONFORMED NAME: Big Cypress Acquisition Corp.
DATE OF NAME CHANGE: 20201120
4
1
ownership.xml
X0306
4
2021-10-22
0
0001833214
SAB Biotherapeutics, Inc.
SABS
0001889694
Carillo Carlos N
2100 E 54TH STREET NORTH
SIOUX FALLS
SD
57104
0
1
0
0
SVP Regulatory Affairs
Employee Stock Option (right to buy)
1.88
2021-10-22
4
A
0
17681
A
2031-05-27
Common Stock
17681
17681
D
Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 24, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.
/s/ Carlos N Carillo
2021-10-26